-
Fuhong Henlius turned losses into Yingcheng Hong Kong Stock Exchange's fourth pick of "B" biopharmaceutical stocks
Time of Update: 2021-07-08
According to the listing rules of the Hong Kong Stock Exchange, unprofitable biotech companies need to add a "-B" mark to the stock name when they are listed .
Fuhong Henlius is the fourth biotech stock to remove the "B" mark after Junshi Biotech (01877.
HK), Cinda Biotech (01801.
-
The clinical trial of Hengrui Medicine's BTK inhibitor SHR1459 tablets was approved by the State Food and Drug Administration
Time of Update: 2021-07-08
Currently, four BTK inhibitors have been approved globally, namely Imbruvica (Ibrutinib), Calquence (Acalabrutinib), Brukinsa (Zanubrutinib) and Velexbru (Tirabrutinib) .
After querying the EvaluatePharma database, the global sales of Ibrutinib, Acalabrutinib, and Zanubrutinib in 2020 are approximately US$7.
-
Net profit increased by more than 500% in the first quarter, the stock price rose sharply, and there are many concerns behind the rapid expansion of Aier Ophthalmology
Time of Update: 2021-07-08
Regarding the large amount of goodwill in 2020, Aier Ophthalmology explained in its annual report as: The acquisition of 37 eye hospitals and clinics in this period, a total of 1,593,154,501.
-
Boan Biological publishes the research results of the new crown neutralizing antibody in a sub-issue of the journal Nature
Time of Update: 2021-07-08
LY-CovMab is a recombinant fully human monoclonal neutralizing antibody that specifically binds to the receptor domain (RBD) of the spike protein on the surface of SARS-CoV-2 with high affinity, and can effectively block the surface of the virus and host cells.
-
200-day countdown to CIIE, Sanofi announces participation in the 4th CIIE
Time of Update: 2021-07-08
During the CIIE last year, the chronic disease management innovation project signed by Sanofi and Shanghai Pudong Software Park has been successfully implemented-the digital medical company "Amulai" was officially completed .
-
Taiji Group Caffeine Citrate Injection Obtained Drug Registration Certificate
Time of Update: 2021-07-08
(abbreviated as: Southwest Pharmaceutical), received a drug registration certificate for caffeine citrate injection issued by the National Medical Products Administration.
66 million yuan, and the total sales in Chinese urban public hospitals in the first half of 2020 were about 113.
-
Aier Ophthalmology 2020 grows against the trend, showing responsibility for fighting the epidemic with one heart
Time of Update: 2021-07-08
Later, as the domestic epidemic situation improved, the temporarily suppressed demand for ophthalmology diagnosis and treatment was gradually released, and the company's performance improved significantly, and the business volume throughout the year did not decrease but increased .
-
Taiping Life’s suspension of short-term health insurance causes controversy, hundreds of agents demand that the company continue to perform
Time of Update: 2021-07-08
The PPT for internal training of Taiping Life Insurance sales agents circulating on the Internet shows that the previous "Medical Wuyou" product promised customers "guarantee renewal to 80/100 years old", and the agents promoted the products to customers in accordance with the training techniques .
-
Yu Xuefeng, Chairman of CanSino Bio: Compared with the new crown vaccine production capacity, I want to raise the issue of production efficiency more
Time of Update: 2021-07-08
On April 21, the National Health Commission stated that there has been no report of thrombosis caused by inoculation of the adenovirus vector new crown vaccine of domestic Cansino Biologics .
How do you view the status of the domestic new crown vaccine supply, production capacity and raw materials?
-
International fund giants substantially increase their holdings of Hengrui Pharmaceuticals Sun Piaoyang personally denounces 316 million overweight new drug companies
Time of Update: 2021-07-08
In 2020, the Oppenheimer Fund perfectly avoided the falling market at the end of the fourth quarter, reducing its holdings of Hengrui by nearly 16 million shares in the second and third quarters, perfectly staggering the downward trend .
-
Veeva Zhao Cong shared: "Six Transformations" of Medical Innovation and Excellence in Medical Affairs Management
Time of Update: 2021-07-08
Medical affairs are moving towards "collaborative", "agile" and "remote" management Under the changes in the external market environment and new trends, as pharmaceutical companies play a key role in promoting medical education and academic exchanges, generating clinical evidence-based medicine data, compliance and risk management, how to keep up with the times?
-
Dejin Medical DragonFly protects the most intimate door
Time of Update: 2021-07-08
On April 15, 2021, Professor Wang Jianan's team from the Second Affiliated Hospital of Zhejiang University School of Medicine used Dejin Medical's DragonFly™ mitral valve clamp system to complete mitral valve repair surgery for a 71-year-old patient with dilated cardiomyopathy .
-
Biosafety (Nantong) New Drug Creation Base Launched and Biotop Animal Brand Launch Conference
Time of Update: 2021-07-08
, Ltd. 10:30-10:50 Base launch and brand launch ceremony & signing ceremony10:50-12:00 Visit to Biosaitu (Nantong) New Drug Creation Base12:00-13:30 lunchIn the afternoon of April 24, 2021, "Innovative Models, Boosting Biomedicine" Forum13:30-13:35 Welcome speech13:35-14:00 Strategy analysis to strengthen the correlation between preclinical efficacy evaluation test results and clinical research Chen Yue, General Manager Chengdu Hetuo Chuangzhan Biotechnology Co.
-
Junshi Bio-Treplimumab first-line treatment of esophageal cancer phase III clinical trial reached the primary endpoint
Time of Update: 2021-07-08
Junshi Biotech announced that the company’s self-developed anti-PD-1 monoclonal antibody drug teriprizumab combined with chemotherapy for the first-line treatment of advanced esophageal squamous cell carcinoma is a randomized, double-blind, placebo-controlled, multi-center phase III clinical study (JUPITER).
-
Siemens Medical helps West China Hospital build a remote imaging scanning platform for medical consortia
Time of Update: 2021-07-08
In the next three years, West China Hospital of Sichuan University will work with Siemens Healthcare to popularize excellent medical resources to all levels of hospitals in the West China Medical Consortium through the “5G remote real-world image inspection platform” , Benefiting dozens of hospitals and millions of patients, and gradually establishing a multi-center expert platform to connect all parts of the country, promote mutual recognition of imaging examination results, promote smart medical care, benefit patients, and warm society .
-
Frontage Pharmaceuticals acquires Ocean Ridge Biosciences to expand genomics services
Time of Update: 2021-07-08
Ocean Ridge Biosciences is located in Deerfield Beach, Florida, and provides genomics services for customers developing new therapies, including complete service solutions for analyzing RNA expression, DNA polymorphism, methylation, microbial composition, and protein biomarkers in a wide range of samples .
-
Hua Medicine's first innovative diabetes drug dozaglietin NDA was accepted by NMPA
Time of Update: 2021-07-08
Dozaglietin has become the first glucokinase activator (GKA) diabetes treatment drug in the world to submit a new drug marketing application, and it is expected to become the first global innovative drug (FIC) to be marketed in China .
-
WOCF establishes urostomy nursing forum to promote professional development in the field of nursing
Time of Update: 2021-07-08
The two experts shared their views and exchanges on topics such as indications, surgical development, complications, stoma care, and postoperative quality of life of patients with urostomy, which brought valuable insights to the promotion of medical and nursing collaboration and the development of disciplines.
-
Sansheng Guojian recombinant anti-IL-17A humanized monoclonal antibody for the treatment of moderate to severe plaque psoriasis phase II clinical trial completed the first subject to be enrolled
Time of Update: 2021-07-08
China's antibody drug pioneer Sansheng Guojian announced that its recombinant anti-IL-17A humanized monoclonal antibody (drug code: 608) is currently conducting clinical research on the treatment of
-
Johnson & Johnson Announces First Quarter Results Report Increased by 7.9% Year-on-year
Time of Update: 2021-07-08
After excluding the net impact of acquisitions, divestitures, and exchange rate conversions, based on business operations, global sales increased by 3.
Among them, a number of drugs in the immunology business performed strongly, including Stelara (increased by 9.
